Clinical Trial

Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated November 8, 2024 (before its estimated April 2025 completion). Its status may not reflect the trial's current state.
Summary
MRD driven study. Addition of gemtuzumab to conventional chemotherapy to reduce MRD of patients with favorable/intermediate-risk AML. Post-consolidation assessment of MRD.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2019-11-15; most recent amendment 2024-11-07.
Status change: Not Yet Recruiting → Recruiting 2021-03-29
Trial Details
NCT Number NCT04168502
Lead Sponsor Gruppo Italiano Malattie EMatologiche dell'Adulto
Conditions Acute Myeloid Leukemia
Enrollment 414 participants
Start Date 2020-09-24
Primary Completion 2025-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2024-11-08